Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.
For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.
Evolocumab will now be available via the Pushtronex system™, designed to deliver 420 mg in a single dose.
Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.
Researchers found that roughly 834 500 Americans have the inherited condition.
Higher numbers of insured leading to more treatment of hypertension, high cholesterol and diabetes.
The FDA has approved the first PCSK9 inhibitor to treat certain adults with high cholesterol.
An FDA advisory committee has recommended approval of alirocumab (Praluent, Regeneron) for treatment of hypercholesterolemia.
The PCSK9 inhibitor evolocumab appears to be safe and effective for reducing LDL cholesterol in older patients.
Review shows no changes for rheumatoid arthritis patients with tumor necrosis factor antagonist treatment.
Two studies show that PCSK9 inhibition lowered LDL cholesterol in heterozygous and homozygous familial hypercholesterolemia.
Long-term statin use among children with familial hypercholesterolemia is associated with normalization of carotid intima-media thickness progression.
Sanofi and Regeneron announced positive results from four phase 3 ODYSSEY trials of alirocumab in patients with hypercholesterolemia.
Amgen announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for evolocumab for the treatment of high cholesterol.
Cutting traditional risk factors could eliminate significant amount of cardiovascular disease
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Gender-Related Association Between Physical Activity, Psychological Status in T2D
- Adverse Neurodevelopmental and Mental Health Outcomes in PCOS
- HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes
- Choroidal Thickness Changes in Patients With Untreated Diabetes
- Pre-Pregnancy Fitness Lowers Gestational Diabetes Risk